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Abstract
Background: Asthma control is influenced by multiple factors. These factors must be considered when appraising
asthma interventions and their effectiveness in the Gulf Cooperation Council (GCC) countries (Bahrain, Kuwait,
Oman, Qatar, Saudi Arabia and United Arab Emirates [UAE]). Based on published studies, the most prevalent asthma
treatment in these countries are fixed dose combinations (FDC) of inhaled corticosteroid and long-acting beta-
agonist (ICS/LABA). This study is a rapid review of the literature on: (a) factors associated with asthma control in the
GCC countries and (b) generalisability of ICS/LABA FDC effectiveness studies.
Methods: To review local factors associated with asthma control and, generalisability of published ICS/LABA FDC
studies, two rapid reviews were conducted. Review 1 targeted literature pertaining to asthma control factors in GCC
countries. Eligible studies were appraised, and clustering methodology used to summarise factors. Review 2
assessed ICS/LABA FDC studies in conditions close to actual clinical practice (i.e. effectiveness studies). Eligibility was
determined by reviewing study characteristics. Evaluation of studies focused on randomised controlled trials (RCTs).
In both reviews, initial (January 2018) and updated (November 2019) searches were conducted in EMBASE and
PubMed databases. Eligible studies were appraised using the Critical Appraisal Skills Program (CASP) checklists.
Results: We identified 51 publications reporting factors associated with asthma control. These publications reported
studies conducted in Saudi Arabia (35), Qatar (5), Kuwait (5), UAE (3), Oman (1) and multiple countries (2). The most
common factors associated with asthma control were: asthma-related education (13 articles), demographics
(11articles), comorbidities (11 articles) and environmental exposures (11 articles). Review 2 identified 61 articles
reporting ICS/LABA FDC effectiveness studies from countries outside of the GCC. Of these, six RCTs were critically
appraised. The adequacy of RCTs in informing clinical practice varied when appraised against previously published
criteria.
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Conclusions: Asthma-related education was the most recurring factor associated with asthma control in the GCC
countries. Moreover, the generalisability of ICS/LABA FDC studies to this region is variable. Hence, asthma patients
in the region, particularly those on ICS/LABA FDC, will continue to require physician review and oversight. While
our findings provide evidence for local treatment guidelines, further research is required in GCC countries to
establish the causal pathways through which asthma-related education influence asthma control for patients on
ICS/LABA FDC therapy.
Keywords: Asthma control factors, Effectiveness studies, ICS/LABA FDC, Gulf cooperation council (GCC) countries,
Clinical practice, Rapid review, Evidence-informed policy-making
Background
The global public health burden of asthma is significant,
with an estimated global prevalence of 358 million [1].
The Disability Adjusted Life Years (DALYs) attributed to
asthma globally across all ages was 23.7 million in 2016
[2]. This chronic condition therefore represents a signifi-
cant burden to healthcare systems and to individuals liv-
ing with asthma. While asthma research has received
extensive attention worldwide, research on asthma con-
trol and the effectiveness of public health interventions
is still limited within the Gulf Cooperation Council
(GCC) countries (namely Bahrain, Kuwait, Oman, Qatar,
Saudi Arabia and the United Arab Emirates [UAE]).
Insight into the prevalence and burden of asthma
within the region has been provided by the SNAPSHOT
programme [3], a study of large random samples from
the general populations of Middle Eastern countries in-
cluding Kuwait, Saudi Arabia and the UAE (Gulf clus-
ter). The reported prevalence of asthma was 6.4% across
all of the assessed Middle Eastern countries and 7.6%
within the Gulf cluster [3].
The extent to which the effects of asthma can be
seen in individual patients, or reduced by pharmaco-
logical or non-pharmacological interventions is known
as asthma control [4]. The Epidemiological Study on
the Management of Asthma in Asthmatic Middle East
Adult Population (ESMAA) re-affirmed the low levels
of asthma control in the GCC countries, with the
highest levels reported as 41% and 42.6% in Qatar
and Kuwait respectively [5].
Numerous risk and prognostic factors have been asso-
ciated with asthma control [6]. These include genetics,
tobacco exposure, occupational exposure, air pollution,
respiratory infection, and adherence to treatment [7, 8].
While factors associated with asthma control are gener-
ally thought to be similar worldwide, the strength of as-
sociation may vary both within and, between different
populations [9]. Knowledge of local factors associated
with asthma control is therefore critical in implementing
effective asthma management strategies. Consequently,
findings from studies conducted within specific popula-
tions of interest, or generalisable to these populations,
are vital in informing asthma management. Despite nu-
merous published studies, there is a paucity of evidence
synthesis on asthma control factors in the GCC coun-
tries. More significantly, evidence relating to the effect-
iveness of asthma interventions in clinical practice
within GCC countries is sparse. Given that the goal of
asthma management is to achieve optimal asthma con-
trol, it is imperative to provide asthma treatment guide-
line developers with timely evidence that is relevant to
the local population.
Inhaled corticosteroid (ICS) and long-acting beta-
agonist (LABA) fixed dose combinations (FDC) are the
most reported therapeutic intervention for asthma man-
agement in the GCC countries, with a significant pro-
portion of patients in the GCC region being in steps 3
and 4 of the Global Initiative of Asthma (GINA) man-
agement guidelines [4, 10]. The place of FDC of ICS and
LABA in the management of asthma is also recognized
in local treatment guidelines within the GCC, such as
the Saudi Initiative for Asthma guidelines [11], the Na-
tional Asthma Management Guidelines in Oman [12]
and the National Clinical Guidelines on the diagnosis
and management of asthma in adults by the Qatar Min-
istry of Public Health [13]. A recent study within the re-
gion has shown that patients on ICS/LABA FDCs were
more likely to achieve asthma control compared to pa-
tients not managed on this therapy [14]. This may pro-
vide possible explanation as to why ICS/LABA FDC is
the choice of many treating physicians within the region.
The use of ICS/LABA in these countries has been re-
ported to range from 73.1% in the UAE to 83.7% in
Qatar, with a similar proportion reported in Saudi Ara-
bia (76.3%) and Kuwait (76.8%) [5]. These estimates in-
clude instances in which ICS/LABA FDC is either used
as the main asthma treatment or in combination with
other therapies.
While the efficacy of different ICS/LABA FDCs has
been established in traditional randomised controlled tri-
als (RCTs) with strict eligibility criteria, their benefit in
actual clinical practice may be reduced by numerous fac-
tors associated with asthma control [15]. Many of these
factors have been reported in the literature, such as
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adherence to treatment, comorbidities, polypharmacy
and education [16]. The extent to which locally relevant
factors are accounted for in effectiveness studies of
asthma therapeutic interventions is therefore important
when determining the generalisability of evidence from
these studies [15]. Moreover, only around 3.3% of pa-
tients from actual clinical practice have been found to be
eligible for inclusion in traditional RCTs [17].
Studies conducted within the GCC countries are pre-
dominantly cross-sectional in nature and have been con-
ducted in different healthcare settings. Most of these
studies are descriptive and therefore only estimate the
prevalence of asthma and, report factors associated with
the disease [10]. While the prevalence of asthma has
been informed by the estimated ranges reported in these
studies [11], a synthesis of important asthma control fac-
tors in these countries will be informative for updates to
local asthma management guidelines and practice. Sys-
tematic literature reviews (SLRs) are highest in the trad-
itional hierarchy of evidence but few evidences of this
type can be found in the region [18–20]. This may be
due to several reasons, including the quality and hetero-
geneity of studies, as well as perhaps the required time
commitment of conducting such extensive reviews [21].
Rapid reviews offer a time-sensitive alternative, using
abridged SLR methods to generate evidence for health-
care decision makers. These reviews provide evidence
summaries that can inform local treatment guidelines
and other public health interventions [22, 23]. Moreover,
rapid reviews can provide useful evidence, specifically on
pharmacological interventions [24]. Such reviews have
proven to be useful in certain healthcare settings as they
can address gaps in knowledge through provision of reli-
able, user-friendly and timely evidence [22, 23].
In the present study, a rapid literature review approach
was used to address two conceptually sequential objec-
tives: Review 1, to ascertain factors associated with
asthma control in the GCC countries (Bahrain, Kuwait,
Oman, Qatar, Saudi Arabia and the UAE); and Review 2,
to assess the effectiveness of ICS/LABA FDC therapy in
asthma control that are generalisable to asthma manage-
ment in the GCC countries.
Methods
We conducted two rapid literature reviews in order to
provide a time-sensitive summary of factors associated
with asthma control in the GCC countries, and ICS/
LABA FDC effectiveness studies in asthma to provide
evidence for policy and practice of asthma management.
Search strategy
A facet analysis was conducted on the respective re-
search questions by identifying relevant search terms
using the Population, Intervention, Comparator,
Outcomes and Study Design (PICOS) framework. Ap-
propriate terminologies were applied in selected biblio-
graphic databases to inform a comprehensive search
strategy (Table 1) [25]. The choice of bibliographic data-
bases for this review was informed by the need to ensure
the respective literature searches were as extensive as
possible thereby reducing the risk of publication bias.
PubMed and EMBASE were chosen as they contain
indexed abstracts for recent publications [26]. The initial
searches were conducted in January 2018 to include
publications up to the date of search. As part of an edi-
torial process to bring the literature coverage up to date,
updated searches were conducted to include literature
up to 4 November 2019. Only search outputs containing
abstracts were considered for screening.
Eligibility of search output
Identified publications were screened for eligibility by
title and abstract. Studies were excluded from the search
if they were: duplicates, irrelevant to the research ques-
tion, studying the wrong intervention or outcome, non-
empirical studies such as review articles, conference pro-
ceedings, guidelines, or conducted in a different base
population. Two reviewers conducted the screening,
with a third reviewer providing input in instances of dis-
crepancy. Pre-defined information from the full articles
of eligible papers was extracted using an extraction grid
created by the review team specifically for this purpose.
Quality assessment
In order to assess the quality of eligible publications,
adapted Critical Appraisal Skills Programme (CASP)
study checklists were used in the respective reviews [27,
28]. We added questions to the checklist to explore the
interrelationships of putative asthma control factors.
These questions were: (i) whether all important con-
founders were identified; (ii) if the method of adjusting
for confounding was reported; (iii) if explanatory vari-
ables modulating the effect size of asthma therapy inter-
ventions were reported; and (iv) if there was a causal
web reported or deducible. These questions were added
to mobilise additional knowledge about asthma control
factors from these studies [29].
The quality assessment of eligible studies in the two
reviews comprised of two parts. First was an assessment
of the internal validity of individual studies. This in-
cluded an appraisal of the study objective in relation to
the definition of exposure and outcome(s) of interest
and statistical analysis conducted, as well as study design
and analysis methods employed to reduce biases. The
second part was an assessment of generalizability of the
study findings; this assessed how findings from each
study related to other available evidence, and their impli-
cations for asthma management guidelines and practice.
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Critical appraisal was not possible in instances where
the full article could not be retrieved. Where critical ap-
praisal was conducted, some factors were not included
in the cluster analysis when these were considered as
proxies of other factors, or mediators of the relationship
between other identified factors and asthma control.
Knowledge-user involvement
Collaboration with a consultant pulmonologist – who is
also a co-author of this research and widely published
on asthma control in GCC countries – was an integral
part of our rapid review process. During the planning
and initiation of the rapid review, his expert contribu-
tions included: insights on putative asthma control fac-
tors of clinical significance in the GCC countries; expert
opinion on reported factors in the context of local
asthma management practices; eliciting the broader
opinions of experts during the presentation of prelimin-
ary results at a scientific congress; and the translation of
wider knowledge to the findings, such as the review of
recent updates to treatment guidelines. Data analysis
was informed by the Cochrane Consumers and Commu-
nication Review Group guide on data synthesis and ana-
lysis [26]. The study results were reported using the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidance [30].
Asthma control factors in the GCC countries – review 1
The search strategy and article eligibility considerations
were guided by the PICOS framework (Table 1) - pre-
sented as a flow diagram in Fig. 1. Articles were included
if they reported univariate or multivariate analysis of
Table 1 Framework and search strategy for analyses
Review 1
PICOS FACET Analysis Terms (January 2018 Search) Terms (January 2018 – November 2019 Search)
Population Patients with asthma Asthma Asthma
Intervention N/A N/A N/A
Comparator N/A N/A N/A
Outcome Factors that are likely to
affect asthma control
Adherence, compliance, education,
dosing frequency inhaler, age, lifestyle,
gender, comorbidities
Adherence, compliance, education, dosing
frequency, inhaler, age, lifestyle, gender,
comorbidities
Setting Gulf Cooperation Council countries Bahrain, Kuwait, Oman, Qatar, Saudi
Arabia and United Arab Emirates
Bahrain, Kuwait, Oman, Qatar, Saudi Arabia
and United Arab Emirates




TIME LIMIT – None EMBASE: Published between 2018 and 2019
PubMed: Publication between 2018/01/01
and 2019/11/04
Other LIMITS EMBASE: Studies in humans, publications
with abstract.
PubMed: None




Population Patients with asthma Asthma Asthma
Intervention ICS/LABA Corticosteroid AND long AND acting
AND agonist
Comparator N/A
Outcome Include all measures of asthma
control in the literature
[No term was adopted as it was
deemed more appropriate to consider
in search screening than to limit by term]
[No term was adopted as it was deemed
more appropriate to consider in search
screening than to limit by term]
Setting N/A
Study design All study types that may be
used in effectiveness research
Effectiveness studies, real world studies,
real life, cohort analysis, retrospective
studies, database studies
RCTs, Randomised Control Trials,
effectiveness studies, real world evidence,
real life studies, real world data, real world
studies
LANGUAGE LIMIT English language Database limit: English language Database limit: English language
TIME LIMIT NONE January 2018 January 2018 – November 2019
Other LIMITS Human studies: randomised controlled
trial, systematic review
ICS Inhaled corticosteroid; ICS/LABA Inhaled corticosteroid/long-acting beta-agonist; LABA Long-acting beta-agonist; N/A Not applicable; PICOS Population,
Intervention, Comparator, Outcomes and Study Design; RCTs Randomised controlled trials
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asthma control factors in Bahrain, Kuwait, Oman, Qatar,
Saudi Arabia or UAE. The CASP Cohort Study checklist
was utilised for the asthma control factors literature crit-
ical appraisal [27].
Cluster analysis in review 1: asthma control factors
Clinically significant asthma control factors were identi-
fied in eligible studies if they were statistically significant
with reported precision (i.e. confidence interval) in
multivariate analysis, or statistically significant with pre-
cision in univariate analysis where multivariate analysis
was not reported. Using a similar approach to a previ-
ously reported study, a clustering method was used to
summarise the different factors reported in the literature
[37]. As asthma control factors reported in individual
publications could be multiple and therefore eligible to
be summarized in multiple clusters, these clusters are in-
dependent of the number of studies reviewed. Principal
summary measures were counts of the number of each
cluster reported in the literature. The resulting clustered
factors were presented using bar graphs to illustrate the
frequency of asthma control factors in the different set-
tings in which they were studied.
Effectiveness studies (RCTs) of ICS LABA – review 2
Our first step after conducting the literature search
was to identify analytical studies that empirically
sought to demonstrate causal relations between ICS/
LABA FDCs and asthma control. This was achieved
by extracting information available on the study de-
sign of individual studies and included information
on the intervention and comparator (where applic-
able), effect measure, sample size and analysis of
confounding. Published opinions and other materials
that were not empirical studies or not relevant to
the review question were excluded. Retained publica-
tions were predominantly observational studies. Due
to the wide spectrum of retrieved observational stud-
ies, and the widely accepted view on the robustness
of RCTs over observational studies in analytical re-
search, we limited our analysis to RCTs [38]. How-
ever, given the review question, there was the need
to distinguish between conventional efficacy RCTs
and effectiveness RCTs by adopting previously pub-
lished criteria [39]. The adapted CASP Randomised
Control Trials checklist was used to appraise the
quality of the eligible publications [28]. Data were
summarised descriptively.
Fig. 1 Asthma control factors in the GCC countries (Review 1): Flow diagram of search strategy/approach. SLR: Systematic Literature Review; GCC:
Gulf Cooperation Council [31–36]
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Results
Asthma control factors in the GCC countries (review 1)
In total, our targeted literature search returned 1201 arti-
cles. Of these, 51 articles met the pre-defined eligibility
criteria and were retained for critical appraisal and analysis
(Fig. 1). Of the eligible literature, the earliest identified
publication on asthma control factors in the GCC coun-
tries was published in 1990. Over 74% (38 articles) were
published between 2010 to date of this review. Thirty-five
articles reported studies conducted within Saudi Arabia,
with three articles from the UAE, five each from Qatar
and Kuwait and one from Oman; two articles reported a
study conducted across multiple countries. No articles
reporting studies conducted in Bahrain were identified.
Quality appraisal
The majority (n = 44) of eligible study publications ad-
dressed a clearly focused research question. Most of the
studies across the GCC countries were conducted in con-
venient samples of patients with asthma (i.e. using a non-
probability sampling method where the study sample was
derived from easy-to-reach patients). Only eight of the
studies included all patients within the sample frame or uti-
lised probability sampling methods. Exposure to factors of
asthma control was accurately measured in 42 of the identi-
fied articles, while asthma control was measured using a
validated tool in 27 studies. Based on the study reports, only
22 studies identified all important confounders and 18 ad-
justed for confounders in their study design and/or analysis.
Based on the reported information about variables collected
from study participants at different time points, the follow-
up of study participants was assessed as complete in 30
studies and of long duration in 10 studies (i.e. studied over
a minimum of 1 year to account for variations in temporal
factors such as seasonality). A total of 36 studies reported
some measure of result precision (mostly confidence inter-
vals). Most studies (n = 41) did not report any form of effect
modification and almost the same number of studies (n =
40) did not report any mediator variable.
Cluster analysis
Factors identified in the literature of asthma control in
GCC countries were varied (Table 2). Following critical
appraisal of eligible publications, the most recurring
asthma control factor cluster was asthma-related educa-
tion (n = 13). This was followed by demography, comor-
bidities and environmental factors clusters (n = 11
respectively). Other asthma control factors clusters were
socioeconomic status (n = 9) and factors related to pa-
tient care (n = 7). Inhalant allergens, smoking and adher-
ence to treatment were equally recurrent (n = 6
respectively) (Fig. 2). The least recurring asthma control
Table 2 Asthma control factors in the GCC countries (Review 1): Factor clusters identified during literature analysis
Factor Clusters Constituent Factors Associated with Asthma Control
Asthma-related education Education about: asthma, asthma medicines, correct use of inhaler device, how to prevent
and treat symptoms, perception on the role of ICS, perception on using ER for asthma care
Environmental factors/exposures Altitude, dust, air pollution, seasonal variations, sandstorms, workplace triggers, thunderstorms,
broken mountains, temperature, atmospheric pressure, incense, wood smoke, household
chemicals, soft drinks consumption
Comorbidities Psychiatric illness (anxiety/depression/stress), allergies (rhinitis, sinusitis, skin allergy), family
history of allergy, GERD, obesity, disability (including work-related disability), respiratory pathogens
Disease severity Actual/perceived disease severity, multiple ER visits/hospital admissions, previous requirement of
systemic steroids
Demographic factors Age, gender, geographical distribution, number of siblings, number of pregnancies, marital status,
nationality, residence (urban/rural)
Smoking Smoking (active and passive)
Asthma triggering drugs ACE inhibitors, β-blockers, aspirin, and NSAIDs
Adherence Adherence/regular ICS use, concomitant use of prophylactic medicines
Socioeconomic status Level of Education, Household income, occupation, employment status, socioeconomic class,
bedroom sharing, daily stress
Factors related to patient care Presence of asthma management protocol, level of physician care, regular follow-ups, medical
insurance, time from diagnosis, length of post-delivery hospital stay, use of herbal medicine
Inhalant allergens House dust mite, cat epithelia, cockroaches, moulds, unsealed mattresses, bedroom carpets, pets,
rye wheat, pollens
History of respiratory complications Previous ICU/Neonatal ICU admission, bronchopulmonary dysplasia, and history of previous
asthma-related hospital admissions, tracheoesophageal fistulae, recurrent aspirations, intubation,
intravenous steroids
ACE Angiotensin-converting enzyme; ER Emergency room; GCC Gulf Cooperation Council; GERD Gastroesophageal reflux disease; ICS Inhaled corticosteroid; ICU
Intensive care unit; NSAID Nonsteroidal anti-inflammatory drug
Similar factors were grouped into the above clusters
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factors were disease severity (n = 3), history of respira-
tory complications (n = 2) and asthma-triggering drugs
(n = 1). The most represented country in the analysis
was Saudi Arabia (35 publications). Other countries on
which published literature on asthma control factors
were identified were Qatar (5 publications), Kuwait (5
publications) and Oman (1 publications) (Fig. 2). The re-
currence of asthma-related education factors associated
with asthma control varied between Saudi Arabia (n =
10), Qatar (n = 2) and Oman (n = 1). Demography, co-
morbidities and environmental exposures were associ-
ated with asthma control in the four GCC countries in
which eligible published studies were identified (Kuwait,
Qatar, Saudi Arabia and UAE). The remaining factor
clusters that were significantly associated with asthma
control were exclusively identified from studies conducted
in Saudi Arabia, namely: asthma triggering drugs, history
of respiratory complications, disease severity, and inhalant
allergens. Socioeconomic status was mostly reported in
Saudi Arabia as a cluster of asthma control factor (Fig. 2).
The most common setting in which studies on asthma
control were conducted were specialist outpatient clinics
(n = 16), followed by community settings (e.g. schools)
(n = 9) and primary care (n = 7) (Fig.3). Of the 16 articles
reporting results from specialist outpatient clinics, the
most commonly reported clusters associated with asthma
control were asthma-related education factors (n = 4) and
environmental factors/exposure (n = 4). When assessed
against healthcare setting, asthma-related education clus-
ter was the most recurrent asthma control factor in the
Emergency Room setting (ER) (n = 5). In the specialist
outpatient setting, asthma-related education (n = 4) and
environmental exposures (n = 4) were most recurrent
asthma control factors clusters. Demography (n = 3), co-
morbidities (n = 3) and socioeconomic status (n = 3) were
also often recurring factors associated with asthma control
in the specialist outpatient setting. In the primary and
community care settings, environmental factors (n = 4),
adherence (n = 4) and inhalant allergens (n = 4) were the
most recurrent asthma control factors. Other factors asso-
ciated with asthma control in the primary and community
care settings are demography (n = 3), comorbidity (n = 3)
and socioeconomic status (n = 3). The most recurring fac-
tors associated with asthma control in inpatient care in-
cluded comorbidities (n = 2), environmental exposure
(n = 2) and history of respiratory complications (n = 2). Of
the eligible publications on asthma control factors in the
GCC countries, 23 studies (45%) were conducted in adult
patient populations only, while 21 studies (41%) were con-
ducted in paediatric patient populations only (Fig. 4).
Fig. 2 Asthma control factors in the GCC countries (Review 1): Total number of articles by country. GCC: Gulf Cooperation Council; UAE: United
Arab Emirates reported; n = total number of articles representing results from country; bar counts number of reports from each country, some
articles reported multiple asthma control factors; Bahrain was assessed per method but provided no reports. One article from Kuwait did not
report any factor cluster
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Difference was seen in the recurrence of socioeconomic
status cluster as being associated with asthma control in
adults [6] compared to paediatric population [2]. Similarly,
factors cluster of patient care was more recurrent in stud-
ies conducted in the adult patient population [5] com-
pared to the paediatric asthma population [2].
Furthermore, adherence to asthma treatment was more
often associated with asthma control in adult patients [4]
than in paediatric patients [1]. Comorbidities, including
disability, in the adult population studies (n = 5) recurred
less to the paediatric population studies (n = 6). (Fig. 4).
Effectiveness studies (RCTs) of ICS/LABA FDC (review 2)
In total, our targeted literature search identified 435 arti-
cles in the EMBASE and PubMed databases. Of these,
61 articles were identified as publications of effectiveness
studies of ICS/LABA FDC, i.e. conducted in broad pa-
tient populations with conditions close to actual clinical
practice (Fig. 5). The earliest year of publication of these
studies was in 2004, with the latest publication in 2017.
The designs of these studies were variable and included
historical cohort studies (n = 39), prospective cohort
studies (n = 8), RCTs (n = 6) and cross-sectional studies
(n = 3). Only the six effectiveness RCTs were retained
for quality appraisal and the extent to which these stud-
ies were distinguished as effectiveness RCTs was de-
scribed (Table 3). The earliest date of publication among
the six effectiveness RCTs was in 2010 and the latest
publications were in 2019.
Quality appraisal
All RCT studies appraised in this analysis addressed
clearly defined questions and assigned patients to treat-
ment groups by randomisation. Based on published in-
formation, five of the six studies had treatment groups
that were similar to each other at the start of each trial.
In one study, the authors reported that patients rando-
mised to experimental ICS/LABA FDC were more likely
to revert to their original treatment. Unlike traditional
RCTs, study investigators were not blinded in any of the
appraised studies – this was expected due to the studies
being conducted in conditions similar to actual clinical
practice.
The treatment effect of ICS/LABA FDC reported in
the appraised studies included : difference in means in
Asthma Control Questionnaire 7 (ACQ7) [40] odds ra-
tios, where changes in Asthma Control Test (ACT)
scores were assessed [41]; hazard ratios where time to
asthma exacerbation was assessed [42]; and relative
rates, where the number of exacerbations per patient per
year was reported [43, 44]. One study measured changes
in fractional exhaled nitric oxide (FeNO) values from
baseline [45]. All but one of the studies [45] reported
95% confidence intervals to indicate the precision of the
treatment effect. In one of these studies, the 95%
Fig. 3 Asthma control factors in the GCC countries (Review 1): Total number of articles by setting. ER: Emergency room; GCC: Gulf Cooperation
Council; n = total number of articles representing results from each setting; bar counts number of reports from each setting. Some articles
reported multiple asthma control factors
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confidence interval for the primary outcome measure in-
cluded the reference value of 1 [44].
There were variable limitations in the generalisability
of the identified ICS/LABA FDC effectiveness RCTs to
the local population in GCC countries. Reasons ranged
from limitations in study design to inferences from stud-
ies on clinical practice. Hozawa et al. [45] had a limited
study duration (8 weeks) and excluded patients with a
history of smoking, thus limiting the generalisability of
the study outcomes. Usmani et al. [40] acknowledge that
the study design might have contributed to the differen-
tial rate of non-completion and missing outcomes. Lack
of clarity on identifying patients suitable for step-down
therapy in routine daily practice [43], and the implica-
tion of potential sub-optimal control in patients who
may request as-needed therapy [44], were some other
factors that limited the application of other study find-
ings to clinical practice.
Two key trends emerged concerning the outcome
measure of the different ICS/LABA FDC studies. The
first was the benefit observed in improving asthma
control factors, which is the main goal of asthma man-
agement. The second was the benefit reported in redu-
cing the number of asthma exacerbations.
Assessment of identified effectiveness RCT studies against
effectiveness studies criteria
Four unique RCTs were identified during the initial lit-
erature search and two additional eligible studies were
identified during the updated search, taking the total
number of identified publications reporting the results
of effectiveness RCTs to six. The six ICS/LABA FDC ef-
fectiveness RCTs had different comparator groups, such
as different doses of the same ICS/LABA FDC, alterna-
tive ICS/LABA FDC, and usual care (including other
therapeutic options).
Most studies recruited patients from primary care set-
tings which suggests that the broadest spectrum of
asthma patients, within the healthcare systems in which
the studies were conducted, are present in this setting.
Study setting was not reported in one study [42]. Patient
eligibility criteria varied across all the studies. The
Fig. 4 Asthma control factors in the GCC countries (Review 1): Total number of articles by age classification (adult and paediatric). n = total
number of articles results from each setting; bar counts number of reports for each age group
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broadest eligibility criteria was in Woodcock et al. [41],
in which patients required a general practitioner diagno-
sis of symptomatic asthma and use of maintenance in-
haler therapy. Stricter eligibility criteria across studies
included stipulation of a 6-month exacerbation-free
period [40] and moderate-to-severe asthma [42]. Two
studies adopted eligibility criteria which required pa-
tients to have a self-reported doctor diagnosis of asthma
and use of a short-acting beta-agonist (SABA) alone [43,
44] or in combination with low-to-moderate dose ICS
[44]. The duration of the patient observation period also
varied amongst the studies. The shortest study duration
was 8 weeks [43] and the longest was 52 weeks [41, 43].
Usmani et al. [40] had a study observation period of 24
weeks, while Aubier et al. [42] had an observation period
of 6 months. Sample size calculations and sample sizes
were reported in all but one study [43]. Asthma control
was measured by either ACT or ACQ7 in four out of six
studies. The two studies that did not assess asthma con-
trol measured rate of, and time to severe exacerbation
[42] and, change in FeNO respectively [45]. The intent-
to-treat analysis was reported in four studies [40, 41, 43,
44] while safety was assessed in all of the studies.
Discussion
We conducted this dual rapid review to provide timely
evidence to inform asthma management guidelines and
practice within the GCC countries. The local popula-
tions in the GCC countries share a common geographic
area known as the Arab peninsular. While anthropology
studies have suggested some genetic heterogeneity, there
are common features among local populations within
the GCC countries [46]. An assessment of local asthma
control factors was conducted and, how generalisable
the evidence on ICS/LABA FDC effectiveness is, given
that this therapeutic approach remains the most preva-
lent in the GCC countries. Our search identified studies
from the GCC countries that reported association be-
tween asthma control and the factors contributing to it.
These studies varied in their design; the majority of
which were cross-sectional. Most studies identified were
descriptive and were conducted in Saudi Arabia. This
was anticipated given that Saudi Arabia has the largest
landmass of the GCC countries [47]. The disproportion-
ate number of eligible publications on asthma control
factors in the GCC countries up until 2018 (n = 32) and
after 2018 (n = 19) may be due to several reasons.
Fig. 5 Effectiveness studies of ICS LABA FDC (Review 2): Flow diagram of search strategy/approach. FDC: Fixed-dose combination; ICS: Inhaled
corticosteroid; LABA: Long-acting beta-agonist; RCT: Randomised controlled trial. [43, 44]
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Notable among the reasons is the significant increase in
medical institutions [48] and academic research [49] in
the GCC countries within a relatively short period of
time.
Our search strategy for the review on asthma control
factors was developed to be as broad as possible. Our
preliminary scoping search had revealed that many
asthma related studies published in the region, particu-
larly those reporting on prevalence, also reported on
asthma control factors. Identified studies were generally
lacking analytical framework to inform on the actual role
of factors beyond association. For example, a number of
factors reported in the literature may have been media-
tors or proxies of other putative factors not directly
measured [50]. This limited our ability to ascertain tem-
poral components of asthma control and also, therefore,
to sometimes distinguish between risk and prognostic
factors [51].
Of all the factors reported to be associated with
asthma control within the GCC countries, asthma-
related education recurred most often. These encom-
passed: education about asthma, asthma medicines and
correct use of inhaler device; how to prevent and treat
symptoms; and perceptions on the role of ICS and emer-
gency room use for asthma care. While studies within
GCC countries did not delineate between formal and in-
formal approaches to asthma-related education, a sys-
tematic review of studies of educational interventions in
asthma management found that delivery methods used
in asthma education interventions were mostly informal
[52]. The review also reported that few of these asthma-
related education interventions were home or commu-
nity based. Education factors relating to patient know-
ledge about their symptoms, perceptions about their
medications, and correct use of their device are all areas
within the scope of the healthcare professional-patient
relationship [53]. Consequently, the lack of review and
physician oversight is one of the contributors to poor
asthma control and may lead to over-reliance on rescue
medication. Studies from other parts of the world have
shown that only around 50% of patients claim to be able
to manage their asthma or have good knowledge about
asthma treatment and adherence to controller medica-
tion [54–56]. Hence, it may not be appropriate for pa-
tients to judge their own symptoms and take decisions
on their therapies without guidance from an appropri-
ately trained healthcare professional [55].
For non-pharmacological interventions, our findings
suggest that significant improvements to asthma man-
agement may help to better address asthma-related fac-
tors and therefore achieve optimal asthma control in the
region. One such asthma management practice is the
provision of asthma educators in all healthcare settings
thereby filling the void due to time constraints of asthma
treating physicians [57].
Other factors associated with asthma control included
demography, comorbidities, environmental factors, fac-
tors related to patient care, smoking, adherence, inhalant
allergens and disease severity. As these clusters are likely
to be interrelated, modifying the most distal in the inter-
relationships of these factors may alleviate asthma con-
trol due to their influence on multiple and more directly
associated factors. Examples of distal factors in chronic
diseases include education and socioeconomic factors
[58]. Further research is required to establish the interre-
lationships of these factors as this is important when de-
veloping public health interventions through multi-
disciplinary approaches to asthma management.
Our review of ICS/LABA FDC effectiveness studies
was insightful. Categorising ICS/LABA FDC studies as
either efficacy or effectiveness studies is best considered
as a spectrum. We explored this spectrum by using pub-
lished criteria to provide an objective assessment of how
well each of the studies could inform local clinical
practice.
In the earlier published studies of ICS/LABA FDCs,
lung function, symptoms, use of rescue medication and
adverse events were most frequently reported. However,
there were differences in the individual trials which
meant that few comparisons could be made [59]. This
necessitated comparative studies in broad asthma patient
populations within clinical practice. The first prospect-
ive, Phase III, pragmatic randomised controlled trial
(RCT) conducted in conditions close to clinical practice,
was reported in 2017 [60]. Healthcare professionals and
payers continue to be in need of such studies for treat-
ments that have newly gained Marketing Authorisation
(MA) [61]. Given the few ICS/LABA FDC effectiveness
RCTs identified, it was not surprising that none were
from GCC countries. It was surprising, however, that
our initial search output – which mostly comprised of
traditional efficacy RCTs – included very few studies
conducted in the GCC countries. The possible reasons
for this are beyond the scope of our review. Neverthe-
less, this finding indicates that healthcare professionals
and treatment guideline developers in the region will
continue to rely on evidence presented in studies con-
ducted elsewhere in order to make local evidence-based
decisions on asthma management. As such, it is import-
ant to assess the generalisability of such evidence to local
clinical practice and the appropriateness of its influence
on local asthma management guidelines and practices of
treating physicians within the GCC countries.
Despite identifying few (six) ICS/LABA FDC effective-
ness studies, there was heterogeneity in how these stud-
ies met the applied criteria [40–45]. A key consideration
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in effectiveness studies is ensuring that the study popula-
tion is broad enough to be representative of the target
patient population. Patient eligibility criteria in the stud-
ies ranged from controlled to partially controlled pa-
tients, as in the case of Usmani et al. [40], to moderate-
to-severe asthma in the case of Aubier et al. [42]. The
eligibility criteria adopted in Usmani et al. [40] was
therefore broader than that applied in Aubier et al. [42].
Other studies defined patients simply by diagnosis of
asthma. Woodcock et al. [41] defined eligible patients as
those with a general practitioner diagnosis, which was
based on medical records. This was likely to be more re-
liable than the self-reported doctor diagnosis adopted by
Beasley et al. [43] and Hardy et al. [44], and may explain
some of the criticisms of the latter two studies [62]. In
the study of Beasley et al. [43], as-needed budesonide-
formoterol reduced the number of exacerbations com-
pared to SABA alone, but the study was conducted in a
population in which SABA alone was not indicated
(GINA step II) [4]. In the case of Hardy et al. [44], their
study of budesonide-formoterol reliever therapy com-
pared to maintenance budesonide plus terbutaline may
not have been conducted in patients with mild asthma
only, as it was apparent that some moderate asthma pa-
tients were included based on the treatments taken.
With respect to study duration, Usmani et al. [40] ac-
knowledged that the 12-week follow-up period in each
phase of their study of fluticasone propionate/formoterol
vs fluticasone propionate/salmeterol was likely to have
been insufficient to capture seasonal variations in
asthma control and exacerbations. This is particularly
important in the GCC countries given the effect of sea-
sonality on asthma control. In contrast, Woodcock et al.
[41] showed that fluticasone furoate/vilanterol signifi-
cantly improved asthma control compared with usual
care, including ICS/LABA combinations, over a 52-week
study. Aubier et al. [42] (6 months observation period)
and Hozawa et al. [45] (8 weeks observation period) are
therefore likely to have had insufficient patient observa-
tion period – though neither study discussed this.
There were significant differences in the sample sizes
of the effectiveness RCTs of ICS/LABA combinations
identified in the review. Usmani et al. [40] acknowledged
that one of the limitations of their study, in which they
assessed change to and step-down from fluticasone pro-
pionate/formoterol, was the small sample of patients
(n = 225) studied. This meant study power was limited
for detecting the predictors of response to step-down
therapy. With a total of 8424 study patients, Aubier
et al. [42] calculated the sample size required for each
group to detect a reduction in the proportion of patients
experiencing a severe asthma exacerbation. The study by
Woodcock et al. [41], with 4233 patients, was reported
to be the largest randomised, comparative effectiveness
study conducted in a population intended to represent
that seen in everyday clinical practice. This study was
powered to detect relative improvements in asthma con-
trol. Both Beasley et al. [43] and Hardy et al. [44] con-
ducted sample size calculations and studied 675 and 890
patients respectively.
Measurement of asthma control, which is the main
goal of asthma management, also varied in the studies.
Different tools were employed to assess asthma control.
Usmani et al. [40] suggested that inappropriate assess-
ment of asthma control might contribute to overtreat-
ment. As measured by the ACQ7, asthma control was
similar between the fluticasone propionate/formoterol
(1000/40 μg) and fluticasone propionate/salmeterol
(1000/100 μg) groups; however, a significantly higher
percentage of patients were controlled on fluticasone
propionate/formoterol (1000/40 μg) when control was
defined according to GINA [42]. However, the view of
the authors was that no standardised questionnaire ex-
ists for assessment of asthma control according to
GINA. Aubier et al. [42] reported no significant effect of
the maintenance dose of budesonide/formoterol on the
risk of exacerbation for patients with a post-
bronchodilator peak expiratory flow value ≥80% pre-
dicted normal who comprised two-thirds of the popula-
tion studied. The authors acknowledged that it was
unexpected that a low peak expiratory flow value was
the only variable predicting response to the higher main-
tenance dose of budesonide/formoterol. This could sug-
gest that asthma outcomes other than time-to-first
exacerbation are more relevant when assessing asthma
patients in actual clinical practice. In Hozawa et al. [45],
the authors were of the view that FeNO represents air-
way inflammation. However, this outcome measure may
be of very limited utility in the GCC countries.
Our dual rapid reviews had some limitations. We were
unable to ascertain how comprehensive our two inde-
pendent review searches were given the abridged SLR
method utilised. Given our search strategy, it is probable
that most of the published literature on asthma control
factors in the GCC countries was identified. While our
search on ICS/LABA FDC effectiveness was also com-
prehensive, it is possible that our initial assessment in
determining effectiveness studies from the search output
may have excluded certain publications of RCTs that
their authors would consider to be closer to an effective-
ness than efficacy study.
In our review approach we relied mostly on published
and readily available information – we did not consult
authors to enquire about any unpublished analysis ad-
dendum to their papers. Hence, any established relation-
ship of the associated factors of asthma control may not
have been considered in our review. The quality of some
of the evidence considered, particularly for the review on
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asthma control factors in the GCC countries, varied con-
siderably. The overall utility of studies on asthma control
factors in our analysis was evaluated in view of the over-
all implication for practice and was also informed by the
insights of our expert knowledge user.
Rapid reviews can provide data needed to address is-
sues such as health system policies and effectiveness.
The World Health Organisation and Cochrane have ac-
knowledged the role of rapid reviews in building
evidence-based policies and practices [23]. A major
strength of our review, which conforms to the World
Health Organisation recommendations on rapid litera-
ture reviews, is that our research team included the end-
user (a Consultant Pulmonologist representing those
who would ultimately use the resulting evidence in clin-
ical practice). Our clinical expert was consulted at all
stages of the review process, providing input on review
planning and initiation, conduct during the review, and
assessment of results. This provides an important insight
into the utility of our review. Moreover, the interdiscip-
linary team involved (including health outcomes scien-
tist, epidemiologist, and pharmacist) enriched the review
and its output.
Conclusion
Within the GCC countries, it is important that the ef-
fectiveness of ICS/LABA FDC is established in the con-
text of local asthma control factors. This means that for
evidence to be generalisable to the region, the studies
from which evidence is generated must account for the
asthma control factors pertinent in the region. This is
achieved when studies are designed to minimise bias
and adjust for putative factors associated with asthma
control. Asthma-related education was the most recur-
rent cluster associated with asthma control in the GCC
countries. Education factors that relate to patient know-
ledge about their symptoms, perceptions about their
medications, and correct use of their device require
physician oversight to ensure patients’ asthma control
and, reduce over-reliance on rescue medication. These
findings limit the local relevance of approaches that
leave most asthma patients to judge their symptoms for
taking medication. This finding is particularly important
in the GCC countries where most patients studied have
been reported to be on ICS/LABA FDCs.
Other factors identified as associated with asthma con-
trol in our study included demography, comorbidities,
environmental factors, factors related to patient care,
smoking, adherence, inhalant allergens and disease se-
verity. These factors re-iterate the need for a multi-
disciplinary approach to asthma management in the
GCC countries.
Generalisability of evidence on the most administered
therapeutic intervention in asthma management in the
GCC countries requires that the studies are conducted
in broad patient populations and in conditions close to
actual clinical practice – as assessed by the effectiveness
criteria utilised in our review. As our review of ICS/
LABA FDC effectiveness studies highlights, the extent to
which they can be considered generalisable to the GCC
countries to influence treatment guidelines and clinical
practice is variable.
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